Oruka Therapeutics, Inc.

ORKA Nasdaq SEC CIK 907654
Follow Oruka Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$50M −65% vs same quarter last year
EPS, diluted -
Operating cash flow −$44.3M −105.2% vs same quarter last year
Operating income −$62.1M −82.2% vs same quarter last year
Net income by quarter
−$30.8M
−$21M
−$24.6M
−$30.3M
−$29.6M
−$31.8M
−$41.2M
−$50M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$105.4M
FY24-−$83.7M
FY23$0−$5.3M
FY22$0−$9.9M
FY21$0−$19.3M
FY20$0−$9.7M
FY19$0−$5.5M
FY18$0−$7.9M
FY17$0−$18.5M
FY16$0−$16.4M
FY15$0−$11.4M
FY14$0−$9.7M
FY13-−$6.9M
FY12-−$4.3M
FY11-−$5.4M
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$88.4M
FY24-
FY23−$5M
FY22−$10.9M
FY21−$18.8M
FY20−$7.7M
FY19−$4.8M
FY18−$8.2M
FY17−$17.5M
FY16−$15M
FY15−$10.5M
FY14−$9.4M
FY13−$5.3M
FY12-
FY11−$7M